Valencia

• Study of neoadjuvant patritumab deruxtecan with or without endocrine therapy in previously untreated patients – VALENTINE trial Ended recruitment
  2023-503403-28-00 4 2022-11-25 treatment naïve patients with HR+/HER2-negative high-risk early breast
• Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U … Ended recruitment
  2023-505772-30-00 5 2022-11-09 Melanoma
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended recruitment
  2024-515637-14-00 5 2022-11-08 Cystic Fibrosis
• Study of pembrolizumab, lenvatinib and chemotherapy combination in first line lung cancer Ended recruitment
  2024-511412-25-00 4 2022-11-07 First line treatment for extensive-stage small cell lung cancer small
• A study into the efficacy and safety of dazucorilant (CORT113176) in patients with Amyotrophic Lateral Sclerosis Ended recruitment
  2024-514082-19-00 4 2022-11-04 Amyotrophic Lateral Sclerosis
• An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) Ended recruitment
  2023-509201-77-00 5 2022-11-02 Hereditary Angioedema
• A Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients with Relapsed/Refractory Multi … Ended recruitment
  2023-505865-94-00 9 2022-10-26 Relapsed/Refractory Multiple Myeloma
• This is a study that will evaluate the safety and efficacy of TOOKAD® (padeliporfin) Vascular Targeted Photodynamic Therapy (VTP) in the Tre … Ended recruitment
  2024-512322-28-00 5 2022-10-25 Low Grade Upper Tract Urothelial Cancer
• A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Ev … Ended recruitment
  2024-514394-22-00 6 2022-10-24 Actinic Keratosis
• Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended recruitment
  2024-517008-12-00 5 2022-10-14 Newly-diagnosed multiple myeloma (NDMM)
• A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin … Ended recruitment
  2023-503467-41-00 5 2022-10-12 Relapsed or Refractory Multiple Myeloma
• Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment … Ended recruitment
  2024-518870-15-00 4 2022-10-03 Multiple Myeloma
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously U … Ended recruitment
  2023-504194-21-00 5 2022-09-13 PD-L1 Positive Metastatic Triple-Negative Breast Cancer
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable … Ended recruitment
  2023-504195-14-00 5 2022-08-31 PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
• Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended recruitment
  2023-507933-12-00 5 2022-08-18 Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
• Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic P … Ended recruitment
  2024-511126-31-00 5 2022-08-16 Non-obstructive Coronary Artery Disease
• Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea … Ended recruitment
  2024-514630-21-00 4 2022-08-11 HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Bre
• A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adults. Ended recruitment
  2023-505255-51-00 5 2022-08-08 Herpes Zoster
• Taletrectinib in ROS1 Positive Lung Cancer Phase 2 Global Study Ended recruitment
  2024-516604-41-00 4 2022-08-08 Non-small Cell Lung Cancer
• Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended recruitment
  2024-511068-10-00 5 2022-08-04 Sjögren’s Syndrome
• A Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors Ended recruitment
  2024-513611-28-00 4 2022-07-29 Metastatic Solid Tumors
• Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n … Ended recruitment
  2023-508559-37-00 5 2022-07-14 Lupus nephritis
• A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic … Ended recruitment
  2023-510019-20-00 5 2022-07-13 Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis
• A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu … Ended recruitment
  2022-500014-26-00 5 2022-06-24 Locally-Advanced unresectable or Metastatic breast cancer (MBC)

Showing 1,153–1,176 of 1,853 trials